CUSIP 698955101 · who reports it, how much, and how much it matters to them
20 of the 720 hedge fund managers we track reported shares of Parabilis Medicines, Inc. (Nasdaq: PBLS) on Form 13F for 30 June 2026. Between them they reported USD 1.1bn. The largest position belongs to Ra Capital Management, at USD 792m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management1 fund on PPLI.com | USD 792m | 6.9% |
| 2 | Cormorant Asset Management1 fund on PPLI.com | USD 126m | 6.5% |
| 3 | Farallon Capital Management56 funds on PPLI.com | USD 65m | 0.3% |
| 4 | Casdin Capital3 funds on PPLI.com | USD 18m | 0.9% |
| 5 | Rock Springs Capital Management2 funds on PPLI.com | USD 16m | 0.8% |
| 6 | Logos Global Management1 fund on PPLI.com | USD 14m | 0.6% |
| 7 | Baker Bros. Advisors2 funds on PPLI.com | USD 14m | 0.1% |
| 8 | Marshall Wace LLP84 funds on PPLI.com | USD 12m | 0.0% |
| 9 | Iconiq Capital13 funds on PPLI.com | USD 9.6m | 0.3% |
| 10 | Kynam Capital Management1 fund on PPLI.com | USD 6.8m | 0.4% |
| 11 | Squarepoint Ops7 funds on PPLI.com | USD 1.3m | 0.0% |
| 12 | Tudor Investment Corporation10 funds on PPLI.com | USD 1.2m | 0.0% |
| 13 | Balyasny Asset Management25 funds on PPLI.com | USD 664,000 | 0.0% |
| 14 | Hudson Bay Capital Management8 funds on PPLI.com | USD 621,000 | 0.0% |
| 15 | Brevan Howard Capital Management39 funds on PPLI.com | USD 618,000 | 0.0% |
| 16 | Burkehill Global Management5 funds on PPLI.com | USD 274,000 | 0.0% |
| 17 | Exoduspoint Capital Management7 funds on PPLI.com | USD 265,000 | 0.0% |
| 18 | Scientech Research2 funds on PPLI.com | USD 262,000 | 0.2% |
| 19 | Two Sigma Investments35 funds on PPLI.com | USD 239,000 | 0.0% |
| 20 | Persistent Asset Partners10 funds on PPLI.com | USD 113,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management | USD 792m | 6.9% |
| 2 | Cormorant Asset Management | USD 126m | 6.5% |
| 3 | Casdin Capital | USD 18m | 0.9% |
| 4 | Rock Springs Capital Management | USD 16m | 0.8% |
| 5 | Logos Global Management | USD 14m | 0.6% |
| 6 | Kynam Capital Management | USD 6.8m | 0.4% |
| 7 | Farallon Capital Management | USD 65m | 0.3% |
| 8 | Iconiq Capital | USD 9.6m | 0.3% |
| 9 | Scientech Research | USD 262,000 | 0.2% |
| 10 | Baker Bros. Advisors | USD 14m | 0.1% |
Parabilis Medicines, Inc. trades under the symbol PBLS on the Nasdaq. Its CUSIP, the code used on Form 13F, is 698955101.
20 of the 720 hedge fund managers PPLI.com tracks reported Parabilis Medicines, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 792m), Cormorant Asset Management (USD 126m), Farallon Capital Management (USD 65m), Casdin Capital (USD 18m) and Rock Springs Capital Management (USD 16m).
20 managers in our coverage reported it, and between them they run 312 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Ra Capital Management, where the position was 6.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Parabilis Medicines, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.